We are the Somatic Cell Nuclear Transfer (SCNT)-based research team that creates engineered, autologous or allogeneic stem cells that can be differentiated into many types of therapeutic cells.

Our center is conducting research and development of autologous cell therapy using somatic cell cloning technology to establish high-quality and high efficiency embryonic stem cell lines through the discovery of epigenetic factors that control reprogramming.

In addition, we are developing safe and high-quality “off-the-shelf” cell therapy products by modifying the gene that regulates donor cell immunity to produce universal donor cell therapy products using advanced somatic cell nuclear transfer (SCNT) technology.

Furthermore, our research aims to develop a high-quality egg culture system for patients experiencing age-related difficulty in fertilization as well as SCNT patients at the CHA Hospital.